Chronic low-grade systemic inflammation — marked by elevated CRP, IL-6, TNF-α, and NF-κB activation — underlies cardiovascular disease, metabolic syndrome, neurodegeneration, and accelerated aging. It arises from gut permeability, visceral adipose inflammation, chronic infection, and immune dysregulation. Peptide research offers targeted anti-inflammatory tools that address the root drivers without broad immune suppression.
1. BPC-157 — NF-κB Inhibition / Gut-Systemic Axis
BPC-157 downregulates NF-κB — the master transcription factor controlling inflammatory cytokine production — across multiple organ systems. It repairs gut barrier integrity (reducing the endotoxin-driven systemic inflammation from intestinal permeability) and directly reduces TNF-α, IL-1β, and IL-6 in inflamed tissue.
Dosing Protocol: 250–500 mcg SubQ daily. Oral BPC-157 (500 mcg arginate form) targets gut-driven systemic inflammation. Stack both routes for maximum effect. Cycle: 8–12 weeks.
2. KPV — Targeted Cytokine Suppression
KPV (Lys-Pro-Val) inhibits NF-κB in immune cells and epithelial tissue, reducing the production of IL-6, IL-8, TNF-α, and other inflammatory cytokines. It is particularly effective in gut and skin inflammation, making it valuable for conditions where these tissue types drive systemic inflammatory burden.
Dosing Protocol: 200–500 mcg SubQ daily. Oral formulation for GI-driven inflammation. Topical for skin-driven inflammation. Cycle: 6–8 weeks.
3. Thymosin Alpha-1 — Immune Regulation / Treg Restoration
When systemic inflammation is driven by immune dysregulation (Th1/Th17 dominance, low Treg activity), Thymosin Alpha-1 restores the immunological balance suppressing pathological inflammatory output. It normalizes the cytokine environment by promoting Treg-mediated immune tolerance.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks, then weekly for maintenance. Cycle: 8–12 weeks.
4. VIP — Broad Anti-Inflammatory Neuropeptide
VIP inhibits multiple inflammatory pathways simultaneously — reducing TNF-α, IL-6, IL-12, and NO synthase in macrophages, inhibiting Th17 differentiation, and promoting anti-inflammatory M2 macrophage polarization. It represents one of the most potent endogenous anti-inflammatory signaling molecules.
Dosing Protocol: 25–50 mcg SubQ or intranasal daily. Cycle: 4–6 weeks.
BPC-157 addresses the gut-driven endotoxin source of systemic inflammation while directly suppressing NF-κB. KPV provides targeted cytokine suppression at the tissue level. Thymosin Alpha-1 corrects the upstream immune dysregulation driving excess inflammatory output. VIP applies broad neuropeptide anti-inflammatory signaling across multiple immune cell types.
- Seiwerth S et al. (2018). BPC-157 anti-inflammatory mechanisms. Peptides.
- Getting SJ et al. (2004). KPV NF-κB inhibition. J Biol Chem.
- Goldstein AL et al. (2018). Thymosin alpha-1 cytokine regulation. Int Immunopharmacol.
- Gonzalez-Rey E et al. (2006). VIP and anti-inflammatory macrophage polarization. PNAS.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).